Highly potent novel opioid receptor agonist in the 14-alkoxymetopon series

Abstract

The newly synthesized 14-alkoxymetopon derivatives, 14-methoxymetopon, 14-methoxy-5-methylmorphinone, exhibit high affinity for the naloxone binding sites in rat brain. A substantial decrease in affinity was observed, in the presence of NaCl indicating a high degree of agonist activity. All three 14-alkoxymetopon derivatives displayed high affinity for [ 3H][D-Ala 2,(Me)Phe 4,Gly-ol 5]enkephalin ([ 3H]DAMGO) binding sites, much less potency toward δ sites and were the least effective at κ sites. Isolated tissue studies using the guinea pig ileum preparation confirmed their high agonist potency. Following administration the new compounds produced naloxone reversible antinociceptive effects and were 130–300 times more potent than morphine in the acetic acid induced abdominal constriction model in the mouse, and the hot plate and tail flick tests in the rat. The compounds also produced dose-dependent muscle rigidity, and potentiated barbiturate-induced narcosis. The in vivo apparent pA 2 values for naloxone against 14-ethoxymetopon and morphine were similar in analgesia, suggesting an interaction with the same (μ) receptor site. The dependence liability of 14-alkoxymetopon derivatives in the withdrawal jumping test was less pronounced than that of morphine in either rats or mice, similar to tolerance to the their analgesic action. It is concluded that the 14-alkoxymetopon derivatives studied are selective and potent agonists at μ opioid receptors, with reduced dependence liability.